1 / 49

ASH 2011 evidence-based practice guideline for ITP

ASH 2011 evidence-based practice guideline for ITP. ITP in the adult Blood. 2011;117(16):4190-4207. Presentor: 周益聖 Instructor: 蕭樑材. 財團法人台灣癌症臨床研究發展基金會. Outline. Grade system of recommendation IWG definition Diagnosis Course Bleeding risk Treatment of fresh case

stephaniemccarthy
Download Presentation

ASH 2011 evidence-based practice guideline for ITP

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ASH 2011 evidence-based practice guideline for ITP ITP in the adult Blood.2011;117(16):4190-4207 Presentor: 周益聖 Instructor: 蕭樑材 財團法人台灣癌症臨床研究發展基金會

  2. Outline • Grade system of recommendation • IWG definition • Diagnosis • Course • Bleeding risk • Treatment of fresh case • IVIG vs High dose MTP + prednisolone vs placebo • HD dexamethasone • Treatment of refractory/relapase cases after initial steroid • Splenectomy • TPO agonists • Rituximab • Take home massage

  3. Grade system of recommendation • 1A, 1B, 1C, 2A, 2B, 2C • Number: strength of recommendation • 1-we recommend.. • 2- we suggest.. • Alphabetical: quality of evidence • A- RCTs or exceptionally strong observation studies • B- RCTs with limitation or strong observation studies • C-RCTs with serious flaws , weaker observations or indirect evidence Blood.2011;117(16):4190-4207

  4. International working group(IWG) definition • Newly diagnosed: diagnosis to 3 months • Persistent: 3 to 12 months from diagnosis • Chronic: more than 12 months Diagnosis 3 months 12 months Newly diagnosed Persistent Chronic Blood. 2009;113(11):2386-2393.

  5. Diagnosis • Recommend • Check HCV and HIV (1B) • Suggest • Further investigation if abnormalities other than thrombocytopenia (including IDA) in the blood count or smear (2C) • Bone marrow examination not necessary irrespective of age with typical ITP(2C) • Insufficient evidence to recommend routine check anti-platelet Ab , APA, ANA, TPO levels Blood.2011;117(16):4190-4207

  6. Causes of Secondary ITP • Antiphospholipid syndrome • Autoimmune thrombocytopenia(eg Evans syndrome) • Common variable immune deficiency • Drug administration side effect • Infection with CMV, Helicobacter pylori, HCV, HIV, varicella zoster • Lymphoproliferative disorder • Vaccination side effect • SLE Blood.2011;117(16):4190-4207

  7. ITP & Anti-plateltAb Flow Cytometry using donor platelets as target cells detects detects autoAb in 70 %(31/44) in ITP SPRCA ( Solid phase red cell adherence assay)for plasma anti-platelet Ab Sensitivity: 50% (22/44), Specificty:100% J Chin Med Assoc 2006;69(12):569-574.

  8. Treatment of fresh case • Suggest • Treat newly diagnosed patients with platelet count <30x10^9/L(2C) • Longer courses of steroid are preferred than short courses of steroid or IVIG as first-line treatment (2B) • IVIG combined with steroid if more rapid increase in platelet count desired(2B) • IVIG or anti-D as first line if steroid contraindicated(2C) • IVIG dose : 1g/Kg as one-time dose, repeated higher doses if necessary (2B) Br J Haematol 1999;107(4):716-719.(1.5g/Kg)

  9. Treatment of fresh case • Suggest • Treat newly diagnosed patients with platelet count <30x10^9/L(2C) • Longer courses of steroid are preferred than short courses of steroid or IVIG as first-line treatment (2B) • IVIG combined with steroid if more rapid increase in platelet count desired(2B) • IVIG or anti-D as first line if steroid contraindicated(2C) • IVIG dose : 1g/Kg as one-time dose, repeated if necessary (2B) Blood.2011;117(16):4190-4207

  10. Course of Severe ITP 72 pts : steroid only ( 1mg/ kg/ day) 9 pts: high dose IVIG (0.5-2g/kg) 28pts: combined both 5 pts: conservative CR:>100X10^9/L PR: 30X10^9/L ~ 100X10^9/L Haematologica 2006;91(8):1041-1045.

  11. Course of Severe ITP without splenectomy Plt>30X10^9/L: 86% at 5 years CR:>100X10^9/L PR: 30X10^9/L ~ 100X10^9/L PR +CR:86% @ 5 yrs CR:61% @ 5 yrs Haematologica 2006;91(8):1041-1045.

  12. ITP – persistent thrombocytopenia & fatal bleeding 47.8% in aged >60 yrs @ 5 yrs Plt<30x10^9/L Fatal bleeding 2.2% in aged <40 yrs @ 5 yrs 76% in aged >60 years at 2 years Non-fatal bleeding Arch Intern Med 2000;160(11):1630-1638.

  13. Treatment of fresh case • Suggest • Treat newly diagnosed patients with platelet count <30x10^9/L(2C) • Longer courses of steroid are preferred than short courses of steroid or IVIG as first-line treatment (2B) • IVIG combined with steroid if more rapid increase in platelet count desired(2B) • IVIG or anti-D as first line if steroid contraindicated(2C) • IVIG dose : 1g/Kg as one-time dose, repeated if necessary (2B) Blood.2011;117(16):4190-4207

  14. IVIG Vs. HDMP for ITP Plt<20x10^9/L HDMP 15mg/Kg/day D1-3 Daily dose<1g IVIG 0.7g/Kg/day D1-3 Prednisolone (10mg) 1mg/Kg/day D4-21 Lancet 2002;359(9300):23-29.

  15. Longer time to loss of response Lancet 2002;359(9300):23-29.

  16. Lancet 2002;359(9300):23-29.

  17. High dose Dexamethasone for ITP Dex 40mg/day D1-4 -Dex 40mg/day D1-4 -Pred 15mg maintian N Engl J Med 2003;349(9):831-836.

  18. -Plt at D10<90X10^9/L->70% relapse -36% required additional treatment -42% had plt >50X10^9/L at 6 months N Engl J Med 2003;349(9):831-836.

  19. High dose Dexamethasone for ITP • Dexamasone 40mg IVA QD x4 days • Every 28 days for 6 cycles • Prednisone at 0.25 mg/kg/day PO • Plt < 20X10^9 /L • Bleeding symptoms related to thrombocytopenia • CR - >150X10^9/L • PR - 50X10^9/L ~ 150X10^9/L • MR( minimal response) • 20X10^9/L ~ 50X10^9/L (Monocenter: 1996 and June 2000 at the Haematology Department of the University La Sapienza of Rome,Hospital Policlinico Umberto I Italy) • 30X10^9/L ~ 50X10^9/L (GIMEMAmulticenter pilot study) • NR( no response) • <20X10^9/L (Monocenter) • <20X10^9/L (GIMEMAmulticenter pilot study) Blood 2007;109(4):1401-1407.

  20. Monocenter trial RFS: 97% at 6 months 90% at 15 months 58% at 50 months RFS RFS: Cycle 6 : 94% at 15 months Cycle 3-4-5: 84% at 15 months RFS according to cycles Blood 2007;109(4):1401-1407.

  21. Blood 2007;109(4):1401-1407.

  22. GIMEMAmulticenter pilot study RFS: <18y/o: 96% at 15 ms >=18y/o: 60% at 15 ms RFS: CR : 87% at 15ms PR+MR:65% at 15ms Blood 2007;109(4):1401-1407.

  23. Treatment of unresponsive or relapse cases after initial steroid • Recommend • Splenectomy for patients failing steroid (1B) • The only treatment for sustained remission off all treatment at 1 year and beyond in a high proportion of patients • Deferred for at least 6 months after diagnosis Blood. 2010;115(2):168-186. • Against further treatment in asymptomatic patients after splenectomy with platelet count >30x10^9/L (1C) Blood.2011;117(16):4190-4207

  24. Chronic ITP post splenectomy Br J Haematol 2003;120(6):1079-1088.

  25. Br J Haematol 2003;120(6):1079-1088.

  26. Truly refractory cases post splenectomy : 5/183(2.7%) Br J Haematol 2003;120(6):1079-1088.

  27. Br J Haematol 2003;120(6):1079-1088.

  28. Chronic ITP after splenectomy failure Gooup 0: spontaneous remission Group 1: response to steroid,danazol,colchicine, vinblastin, rituximab,interferon Group 2:response to oral cyclophosphmide, azathioprine,cyclosproine Group 3: response to IV cyclophosphmide or C/T Blood 2004;104(4):956-960.

  29. Blood 2004;104(4):956-960.

  30. Blood 2004;104(4):956-960.

  31. Laprascopic vs. open splenectomy • Both offer similar efficacy (1C) Blood 2004;104(9):2623-2634 Surg Endosc 2006;20(8):1208-1213. • 2010 CDC recommend • pneumococcal and meningococcal vaccination for elective splenectomy • One dose of H influenzae type b is not contraindicated before splenectomy Blood 2007;109(4):1401-1407.

  32. Treatment of unresponsive or relapse cases after splenectomy • Recommend • TPO agonists for risk of bleeding who relapse after splenectomy or who have contraindication to splenectomy failing at least one other therapy (1B) • Suggest • TPO for risk of bleeding who failed one line of therapy (steroid or IVIG) and s/p no splenectomy (2C) • Rituximab for risk of bleeding who failed one line of therapy (steroid , IVIG or splenectomy) (2C)

  33. Blood.2011;117(16):4190-4207

  34. Eltrombopag & ITP 50 mg or placebo PO once daily for 6 weeks Increased from 50 mg to 75 mg after 3 weeks in patients with platelet counts less than 50 000 per μL Lancet 2009;373(9664):641-648.

  35. Lancet 2009;373(9664): 641-648.

  36. Lancet 2009;373(9664):641-648.

  37. Romiplostim & ITP Lancet 2008;371(9610): 395-403. Splenectomised:3ug/Kg Non-splenectomised:2ug/Kg SC QW for 24 weeks To keep Plt 50×10⁹/L to 200×10⁹/L.

  38. Lancet 2008;371(9610): 395-403.

  39. Lancet 2008;371(9610): 395-403.

  40. TPO agonists • US FDA approval: chronic ITP with insufficient response to steroid, IVIG , or splenectomy • Thrombocytopenia recurs or worsen if suddenly abrupted • Increased risk of portal venous thrombosis in chronic liver disease Hematol 2010;47(3):289-298. • Increased marrow reticulin fibrosis in 10/271 in the romiplostin trials Blood 2009;114(18):3748-3756.

  41. Rituximab & ITP • Weekly infusion of 375mg/m2 for 4 weeksin 16/19 studies Ann Intern Med 2007;146(1):25-33.

  42. Rituximab response • 30% at one year J Support Oncol 2007;5 4 suppl 2:82-84. 2007. • 9/26 (35%) had long-term response • median follow-up of 57 months (range 39–69) • 11/26 (42%) did not necessitate further therapy Eur J Haematol 2008;81(3):165-169.

  43. Take home masage • Treat newly diagnosed patients with platelet count <30x10^9/L • Longer courses of steroid are preferred than short courses of steroid or IVIG as first-line treatment • Splenectomy for patients failing steroid • Against further treatment in asymptomatic patients after splenectomy with platelet count >30x10^9/L • TPO agonists for risk of bleeding who relpase after splenectomy or who have contraindication to splenectomy failing at least one other therapy • Rituximab for risk of bleeding who failed one line of therapy (steroid , IVIG or splenectomy)

  44. Take home masage • Treat newly diagnosed patients with platelet count <30x10^9/L • Longer courses of steroid are preferred than short courses of steroid or IVIG as first-line treatment • Splenectomy for patients failing steroid • Against further treatment in asymptomatic patients after splenectomy with platelet count >30x10^9/L • TPO agonists for risk of bleeding who relpase after splenectomy or who have contraindication to splenectomy failing at least one other therapy • Rituximab for risk of bleeding who failed one line of therapy (steroid , IVIG or splenectomy)

  45. Take home masage • Treat newly diagnosed patients with platelet count <30x10^9/L • Longer courses of steroid are preferred than short courses of steroid or IVIG as first-line treatment • Splenectomy for patients failing steroid • Against further treatment in asymptomatic patients after splenectomy with platelet count >30x10^9/L • TPO agonists for risk of bleeding who relpase after splenectomy or who have contraindication to splenectomy failing at least one other therapy • Rituximab for risk of bleeding who failed one line of therapy (steroid , IVIG or splenectomy)

  46. Take home masage • Treat newly diagnosed patients with platelet count <30x10^9/L • Longer courses of steroid are preferred than short courses of steroid or IVIG as first-line treatment • Splenectomy for patients failing steroid • Against further treatment in asymptomatic patients after splenectomy with platelet count >30x10^9/L • TPO agonists for risk of bleeding who relpase after splenectomy or who have contraindication to splenectomy failing at least one other therapy • Rituximab for risk of bleeding who failed one line of therapy (steroid , IVIG or splenectomy)

  47. Take home masage • Treat newly diagnosed patients with platelet count <30x10^9/L • Longer courses of steroid are preferred than short courses of steroid or IVIG as first-line treatment • Splenectomy for patients failing steroid • Against further treatment in asymptomatic patients after splenectomy with platelet count >30x10^9/L • TPO agonists for risk of bleeding who relpase after splenectomy or who have contraindication to splenectomy failing at least one other therapy • Rituximab for risk of bleeding who failed one line of therapy (steroid , IVIG or splenectomy)

  48. Take home masage • Treat newly diagnosed patients with platelet count <30x10^9/L • Longer courses of steroid are preferred than short courses of steroid or IVIG as first-line treatment • Splenectomy for patients failing steroid • Against further treatment in asymptomatic patients after splenectomy with platelet count >30x10^9/L • TPO agonists for risk of bleeding who relpase after splenectomy or who have contraindication to splenectomy failing at least one other therapy • Rituximab for risk of bleeding who failed one line of therapy (steroid , IVIG or splenectomy)

  49. Thanks for your attention!

More Related